

Dana F. Flavin, M.D.

Email:
drflavin@collmed.org

Medical license: Germany, #310011
Medical license: Ireland, #422036
Additional education: Naturopathic License Germany

www.collmed.org

EDUCATION:

Innsbruck, Austria

Leopold Franzens University	Doctor of Medicine	1998-
	Medicine/Biochemical Pharmacology	1999

Munich, Germany

Technical University Medical School	Medical Boards Part I/Germany	1991-1996
-------------------------------------	--------------------------------------	-----------

Washington, D. C., USA

Howard University,	MS Nutrition/Biochemistry, summa cum laude	1986
Georgetown University Medical School	Gross Anatomy, Honors	1975

Chicago, IL, USA

Chicago University, Finch University of Health Sciences	Pharmacology, Ph.D. Candidate	1972-5
Part I, Medical Boards	Loyola University School of Medicine	1974
Loyola University	BS Psychology/Chemistry	1972

Medical Training

Bad Heilbrunn, Germany

Internal Medicine/Oncology Advisor	Leonardis Oncology Klinik	2000-2004
------------------------------------	----------------------------------	-----------

Berg, Germany

Surgery	Starnberg Community Hospital	1998
General Medicine	Dr. Reinhard Luyken Private Practice	1993
Internal/Intensive Medicine	Argirov Klinik/Schon Klinik	1993
Psychiatry	Rottmannshoehe Heckscher Klinik	1992

PROFESSIONAL POSITIONS:

Professor (Hon), Faculty of Health and Life Sciences	DeMontfort University	2015-
Pharmacology	Leicester, UK	
Stemtide, Inc. Medical Director	Greenwich, CT, USA	2010
The Foundation for Collaborative Medicine and Research	Washington, D. C., USA	2001-present
Executive Director/Medical Director www.collmed.org 501c3		
Flavin Pharmaceuticals, Inc	Greenwich, CT	2008-2010
Chairman		
Dancour, LLC	Greenwich, CT	2009
Chairman		
IMRAC, Haus Burkstetten	Berg, Germany	1999
International Medical Research & Consulting		
Bristol Myers Squibb	Brussels, Belgium	1999
Oncology/Advisor		

Dana F. Flavin, M.D.

Email:
drflavin@collmed.org

Medical license: Germany, #310011
Medical license: Ireland, #422036
Additional education: Naturopathic License Germany

Novartis Consumer Health (Ciba-Geigy) Medical/ Scientific Advisor New Drug research and Development	Nyon, Switzerland	1997 - 1998
BASF Science Consultant Vitamins and cancer	Ludwigshafen, Germany	1987 - 1989
The Nutrition Foundation Science Advisor to the President	Washington, D. C.	1982 - 1985
Food and Drug Administration Science Assistant to the Associate Bureau Director for Toxicology Pharmacologist	Washington, D. C.	1979 - 1982 1980 - 1982 1978 - 1979
Warren - Teed Pharmaceuticals Sales and Marketing Representative	Columbus, Ohio	1977 - 1978
Consultant , Science/ Pharmacology Morris And Ward Consultants Southeast Community Hospital	Washington, D. C. 1977 - 1978 1975 - 1977	1975 - 1978

PATENTS:

U. S., Patent Application	Viral Hepatitis Treatment. 531,300	2012
Germany, Patent Registration	Combination Preparation for Viral diseases. 103 40 845.2	2004
	Rheumabehandlung/Arthritis Treatment. Patent Pending	2004
German Patent Registration	Regeneration formula	2009
US Provisional Patent	Regeneration formula	2009

LANGUAGES: Fluent: English, German, Spanish

COMPANY CONSULTATION AND PRESENTATIONS:

BASF	Nutrients and Cancer Prevention
Novartis	Viral toxicities and Therapies
Roche Pharmaceuticals	New Cancer Therapy Development
Bionorica	Phytopharmacology and Disease Treatment
Bristol Myer Squibb	Translational Oncology
Pfizer	Mechanism of Cancer Growth and Immune Suppression

Research Areas:

Viruses: Epstein Barr Virus, HBV, HIV,

- Autoimmune Diseases: Asthma, Colitis Ulcerosa, Rheumatoid Arthritis, Multiple Sclerosis. Lupus Erythematosus, Morbus Crohn, Graves Disease, Hashimoto's disease:

Dana F. Flavin, M.D.

Email:
drflavin@collmed.org

Medical license: Germany, #310011

Medical license: Ireland, #422036

Additional education: Naturopathic License Germany

- Cancer :

Cervix, Ovarian, Colon, Breast, Acute myelogenous leukemia, Non Hodgkin's Lymphoma, Medullary thyroid cancer

ABSTRACTS:

D. F. Flavin. Tryptamine Receptors in the Frog Heart Ventricle. Sigma Xi, 1973

W. A. Pedemonte, D. F. Flavin, H. C. Sabelli. Indolacetate Activation of Tryptamine Receptors in the Frog Heart. The Pharmacologist 15 (2), 135, 1973

D. F. Flavin. Behavioral and Electrophysiological Effects of Phenylethanolamine - A Putative Neurotransmitter. Sigma Xi, 1974.

D. F. Flavin - Koenig. What Do We About Orthomolecular Therapy? 34. Medicine week Conference. Baden - Baden, Germany, 2000.

PRESENTATIONS:

Indolacetate activation of Tryptamine Receptors in the Frog Heart. American Society for Pharmacology and Experimental Therapeutics. Eastern Michigan University. Ypsilanti, Michigan, 1973.

Behavioral and Electrophysiological effects of Phenylethanolamine, a Putative Neurotransmitter. Sigma Xi, Chicago Medical School. Chicago, Illinois, 1974.

The Effects of Pargyline on the Electrical Activity of the Membrane. George Washington University. Washington, D. C., 1980.

Your Body's Future. Nutrition and Health, World Future Society, Washington, D.C. Chapter, 1981.

Multiple Modalities in Tumor Prevention and Treatment. Cancer Conference. University of Arizona. Tucson, Arizona, 1982.

Cancer Prevention. Hillside Hospital, Livingston Clinic. San Diego, California, 1982.

Nutritional Alterations in the Biochemistry of Tumor Promotion. F.D.A. Washington, D.C., 1982.

Nutritional Effects in Tumor Promotion. Institut Suisse de Experimentale sur le Cancer, ISREC. Epalinges sur Lausanne, Switzerland, 1983.

Nutrition and Cancer. American International Hospital. Zion, Illinois, 1983.

Nutritional Factors that Inhibit Tumor Promotion. North Carolina State University. Raleigh, North Carolina, 1984.

Nutrients in Cancer Prevention. Instituto Superiore di Sanita. Rome, Italy. 1984.

Nutrients and Oxygen Radical Interactions in Tumor Promotion. National Institute of Health National Cancer Institute. Bethesda, Maryland, 1985.

Molecular Changes in Tumor Promotion and Relationship to Oxygen radicals. Gesellschaft für Strahlen - und Umweltforschung (Radiation Research Center). Munich, Germany, 1987.

Nutritional Prevention in Cancer. National Congress on Nutrition and Cancer. Trieste, Italy, 1988.

Antioxidants in Cancer Prevention. International Association of Vitamins and Nutritional Oncology. Charleston, South Carolina, USA, 1989.

Oxygen Radicals in Neurological Toxicity. Neurology Disease Conference, All India Institute for Medical Research. New Delhi, India, 1991.

Oxygen Radicals in Liver Disease. Oxygen Radical Conference, Semmelweis University. Budapest, Hungary, 1993.

Dana F. Flavin, M.D.

Email:
drflavin@collmed.org

Medical license: Germany, #310011

Medical license: Ireland, #422036

Additional education: Naturopathic License Germany

New Treatments in Hepatitis, Technical University Medical School/Glaxo Wellcome. Munich, Germany, 1994.

Xanthine Oxidase and Nitric Oxide Synthase in Viral Disease: Reversal of Hepatosplenomegaly in EBV Infected Children in 24 - 48 Hours. LMU/ GroBhadern Hospital, MED POLY II, 1994.

Immune Modulation in Viral Hepatitis Treatments, New Drug Development. ESSEX Pharm. Munich, Germany, 1995.

New Viral Treatments. Developments for Future Pharmacological Applications. Novartis/Ciba - Geigy. Nyon, Switzerland, 1997.

The Role of Nitric Oxide Synthase in Disease and Toxicity. Boehringer Mannheim/Hoffman - La Roche. Penzberg, Germany, 1997.

New Concepts in Drug Development: The Mechanism of Natural Inhibitors of Viral Replication and Toxicity. Bionorica, Arzneimittel, Neumarkt, Germany, 1999

What Do We Know About Orthomolecular Therapy, Cancer: Replication & Immune Suppression Mechanisms of Nutrient Supplements, 34 Medicine Week Conference, Baden - Baden, Germany, 2000.

Integrated Therapy in Cancer Treatment, Cross Talking at the Cellular Level. Centro Prevenzione Salute. Livorno, Italy, February 16, 2002.

The Application of Natural Substances in Tumor Therapy: The Oncology Patient. Community Hospital at Hall, in Tirol (Sponsor). Hilton Hotel, Innsbruck, Austria, Nov 9, 2002.

Integrated Therapy in Cancer Treatment, Cross Talking at the Cellular level. Centro Prevenzione in Oncologie. Giornata Internazionale di Studio, Attualita E Prospettive. Rome, Italy, Nov 13, 2003.

Health Forum Conference, Nutrients and Nutrition in Cancer Prevention and Treatment. Hilton Hotel, Munich, Germany, June 3, 2004.

Integrative Medizin in der Onkologie, Leonardis Klinik, Bad Heilbrunn Germany: "Increased Response in Cancer Therapy through Molecular biology", October 16, 2004.

Prevention instead of Intervention, Leonardis Klinik, Bad Heilbrunn, Germany
"Multifactoral Preventive Measures against Cancer", June 25, 2005.

Nutritients in Cancer Therapy. C.A.R.E. Meeting, Methodist church. Ridgewood, New Jersey, November 10, 2005.

Understanding Cancer, International Research in Therapy. C.A.R.E Meeting, December 8, 2005.

Preventing Cancer, Cos Cob Library, Cos Cob CT, April 2007.

Anti Cancer and Anti Aging, Greenwich Library, Greenwich CT. May, 2007

"Integrative Medicine in Antiaging" Anti Aging and Integrative Medicine, Rome Italy, March 2009

"Integrative Medicine in Oncology", Integrative Oncology conference, Rome Italy, March 2009

Reversing Cancer with Biochemistry, DeMontfort University, Leicester, UK February, 2016

PUBLICATIONS:

Differential Effects of Two Putative Neuromodulators, 2 - Phenylethylamine and Phenylethanolamine. H. C. Sabelli, A.J. Vasquez, and D. F. Flavin. **The Society of Neuroscience**, 1974.

Behavioral and Electrophysiological Effects of Phenylethanolamine and 2 - Phenylethylamine. H.C. Sabelli, A.J. Vasquez, and D. F. Flavin. **Psychopharmacologia**, 42 (2), 117 - 125, 1975.

Dana F. Flavin, M.D.

Email:
drflavin@collmed.org

Medical license: Germany, #310011

Medical license: Ireland, #422036

Additional education: Naturopathic License Germany

Cimetidine, an Antihistaminic. D. F. Flavin. **Monograph for the American Society of Hospital Pharmacists**, January, 1978.

Neurobehavioral Test Outline for Drug and/or Chemical Toxicity Studies and Evaluations. D. F. Flavin. Division of Toxicology, F.D.A., February, 1979.

Carcinogens and Steroid Receptors. D. F. Flavin. **Harvard Magazine**, Letter, 1981.

The Effects of Soybean Trypsin Inhibitor on the Pancreas of Animals and Man. Review. D. F. Flavin. **Veterinary and Human Toxicology**, 24, 25 - 28, 1982.

Nutritional factors with the Potential to Inhibit Critical Pathways of Tumor Promotion. D. F. Flavin, A. C. Kolbye, Jr. in **Modulation and Mediation of Cancer by Vitamins** (eds., F. L. Meyskens, K. N. Prasad) pp. 24 - 32, Karger, Basel, Switzerland, 1983.

Generalized Cellular Toxicity in Toxic Hyperplasia and Tumor Promotion. D. F. Flavin and C. J. Carr. Appendix C, Response By the Nutrition Foundation, Inc. to the Office Science and Technology Policy: Chemical Carcinogens, Notice of Review of the Science and its Associated Principles, Federal Register Draft Document, May 22, 1984.

Toxicity, Tumor Promotion and Carcinogenesis in Relation to Excessive Dosage. D. F. Flavin, **Regulatory Toxicology and Pharmacology**, 4, 372 - 379, 1984.

Cancerous Esoterous. D. F. Flavin, in **Advances in Free Radicals, Biology and Medicine**, (ed. W. A. Pryor) Academic Press, Vol. 2, 445 - 451, 1986.

The Role of Putative Chemopreventive Nutrients, Retinoids, Tocopherols, Ascorbic Acid, and Selenium, in Cancer Induction. D. F. Flavin, (summa cum Laude) Masters Thesis, Howard University, Washington, D. C., 1986.

A Common Enemy (Peroxyxynitrite). D. F. Flavin - Koenig, **The New Zealand Medical Journal**, Vol. 108, pg. 89, 1995.

The reversal of Epstein Barr Virus Induced Hepatosplenomegaly in 24 Hours with Inhibitors of Xanthine Oxidase and Nitric Oxide Synthase. D. F. Flavin - Koenig and W. Tschollar, **The New Zealand Medical Journal**, 22 March, pg. 106 - 107, 1996.

What Do We Know About Orthomolecular Medicine?: Cancer: Replication and Immune suppression, Mechanisms of Nutrient Supplements. **34. Medizinische Woche**, 28. October to 3 November, (Karl F. Haug Verlag, in MVH Medizinverlage Heidelberg GmbH & Co. KG,) Manuscript accepted. 2000/2001.

Reversing Splenomegalies in Epstein Barr Virus Infected Children: Mechanisms of toxicity in Viral diseases, Dana F. Flavin, **The Journal of Orthomolecular Medicine**, Second Quarter, 21:2, Pg 95-101, 2006.

A Lipoxygenase Inhibitor in Breast Cancer Brain Metastases, D.F.Flavin, **J Neurooncology**, 82:91-93, 2007.

Non Hodgkins lymphoma reversal with DCA,Dana F. Flavin, **J of Oncology**, doi:10.1155/2010/414726, acpt.July23, 2010

Medullary Thyroid Cancer Relapse reversal with DCA, Dana Flavin. **Oncology Letters**,1:889-891, 2010.

MOLECULAR ALTERATIONS IN TUMOR PROMOTION AND CANCER, Book, Amazon 2015

DNA Transcription Regulation by Biochemistry and Physics: A Review, DF Flavin, **Journal of Genetics and DNA Research**, September 26th, 2018

The Complexity of Interactions in Transcription and Cell Replication: Biochemistry and Physics, DF Flavin, **Journal of Genetics and Cell Biology**, February 3rd, 2020

Dana F. Flavin, M.D.

Email:
drflavin@collmed.org

Medical license: Germany, #310011

Medical license: Ireland, #422036

Additional education: Naturopathic License Germany

A theoretical model for an electromagnetic antenna induction of virtual T cells, Massimo Fioranelli, Dana Flavin and others, **Springer Verlag/Springer Nature**, Accepted April 23rd, 2021

POSTERS:

The Reversal of Hepatosplenomegaly in EBV infected children

Gesellschaft fur Strahlen Forschung, Dr. med Dana F. Flavin - König
Neuherberg, Germany, 1996.

Annual Conference Effect of Lactoferrin in Cancer and G.I. Diseases: Dr. D. F. Flavin - Koenig and Massimo Bonucci. Capri, Italy, May 2003.

RADIO & TELEVISION INTERVIEWS:

WBAI New York. February 2005, July 2005, November 2005, December 2005.

The Robert Scott Bell Show, Silver hydrosol. 2008

East Idaho News, Health show, March, 2009

WGCH Greenwich CT. USA: Wednesday Health Program/Weekly 2010.
Cancer, Beauty, General health, Heavy metals, and mold.

Television Interviews: **CBN News**, The Toxicity of Corn Syrup, Feb 4, 2009.

Channel 12 News, CT. Herbs and Cancer, March 10, 2010;

Health Issues from House Mold, March 30, 2010

Eurovision, Stockholm Sweden, New therapies in Cancer with DCA. May, 2010

AWARDS: Women of Innovation in Science and Medicine, Connecticut Technology Council, January 30, 2008

Official Citation: Attorney General Richard Blumenthal and Governor Jodi Rell, Ct.

GRANTS and FUNDING:

NCI Grant review, **Breast Cancer Advisory Board**

FDA Protocol: **Neurological Examination for Toxicology, FDA**

Abbott Labs: **\$50,000 Animal Research**

FCMR: **\$150,000 contributions received for Cancer Research**

Technical University, Munich: **Glaxo, Research \$100,000 Protocol Review, Internal Medicine**